Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Jyra Health vs Kin Meds

Jyra Health
Graded #123

Lower grade

vs+3.3000000000000114
Kin Meds
Graded #75

Higher grade

The verdict

Kin Meds takes it — 72.9/100 to 69.6/100.

Kin Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kin Meds is a LegitScript-verified telehealth platform offering both compounded GLP-1s (semaglutide from $199/mo, tirzepatide from $249/mo) and brand-name FDA-approved options including Wegovy injection and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKin Meds +2
72
74
Dose & formulationKin Meds +29
64
93
Clinical oversightJyra Health +8
82
74
Labs & monitoringEven
53
53
FulfillmentJyra Health +16
88
72
Contract termsKin Meds +6
49
55
Jyra Health · left barKin Meds · right bar

The numbers

MetricJyra HealthKin Meds
WeighScore69.6/10072.9/100
GradeCC
Scorecard rank#123#75
Semaglutide$99/mo (starting dose, plus a separate fee, compounded)$149/mo (brand Wegovy)
Tirzepatide$133/mo (starting dose, promotional rate, compounded)$149/mo (brand Zepbound)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Jyra Health

Graded #123 · C

Strengths

  • Among the lowest compounded pricing — semaglutide from $99/mo and tirzepatide from $133/mo, with no membership and no hidden fees
  • Board-certified providers in all 50 states; no insurance required and free express delivery
  • Offers both compounded semaglutide and tirzepatide, plus a longevity track
  • Full legal suite published (Privacy, Terms, HIPAA, Refunds & Cancellations)

Where it loses points

  • The $133/mo tirzepatide price is flagged 'limited time' — verify current pricing before enrolling
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Zepbound, Ozempic, or Mounjaro
  • Displays a self-hosted LegitScript badge but no verifiable seal or listing
  • Compounding pharmacy not named; appears to be a newer, smaller clinic (~300 patients/month)
Kin Meds

Graded #75 · C

Strengths

  • Publicly lists $199/mo compounded semaglutide and $249/mo compounded tirzepatide
  • Brand-name options too — Wegovy injection and pill, Zepbound, Foundayo from $149/mo entry pricing
  • LegitScript verified
  • Clearly identifies itself as the intake platform and a licensed third-party pharmacy as the dispenser
  • Broad longevity menu (Sermorelin, NAD+, Glutathione) plus TRT, hair, skin, and sexual health

Where it loses points

  • Legal entity name and state of incorporation not publicly disclosed
  • The third-party pharmacy partner isn't named, and Kin Meds isn't itself a licensed pharmacy
  • Per-state availability not listed
  • $149/mo brand pricing is the insured entry tier — cash-pay patients should expect higher real costs
  • Lab work and dose-titration support not clearly described

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard